TCT 2019: TRILUMINATE feasibility study meets both the primary safety and performance endpoints

TriClip New data indicate that a novel transcatheter system for tricuspid valve repair (TriClip, Abbott) was safe and associated with strong clinical improvement at six-months—including a reduction in tricuspid regurgitation and improvement in quality of life—in patients with severe tricuspid regurgitation. The findings were presented at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) [...]

2019-10-01T13:20:16+00:00October 1st, 2019|Tags: , , |

TCT 2019: Low rate of MACE at 12 months with “world’s thinnest stent”

K Sivaprasad (Govt TD Medical College, Alappuzha, India) reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA) yesterday that the Evermine 50 stent (Meril Life), which has a strut thickness of 50μm, is associated with a low rate of major adverse events (MACE) at 12 months. Previous studies have [...]

2019-09-28T17:25:44+00:00September 28th, 2019|Tags: , , , , |

TCT 2019: System for managing deep vein reflux wins Shark Tank award

Source: CRF This morning at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA), InterVene won the TCT-Shark Tank Innovation Competition for its novel endovenous system (BlueLeaf) for forming valves in patients with deep vein reflux and/or chronic venous insufficiency. The award, which is supported by the Jon DeHaan [...]

2019-10-07T10:37:26+00:00September 27th, 2019|Tags: , , , |

TCT 2019: Interim analysis indicates favourable safety profile for AccuCinch

AccuCinch Today at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA), data from an interim analysis of heart failure patients treated in the CorCinch FMR study were presented. These data show, a press release reports, that the AccuCinch ventricular repair system (Ancora Heart) is associated with a favourable safety [...]

2019-09-26T02:50:32+00:00September 26th, 2019|Tags: , , |

MedAlliance receives FDA Breakthrough Device Designation for its sirolimus-eluting balloon for below-the-knee lesions

MedAlliance has been awarded FDA Breakthrough Device Designation for the Selution SLR, which is a sustained limus release drug-eluting balloon catheter for the treatment of below-the-knee disease. According to a press release, the company was the first drug-eluting balloon company in the world to receive FDA Breakthrough Device Designation status for the treatment of [...]

2019-10-01T14:53:22+00:00September 26th, 2019|Tags: , , , |

TCT 2019: Henry V can inspire us to develop innovative techniques for reducing radiation exposure

During a session on radiation protection technologies at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25­–29 September, San Francisco, USA), Lloyd W Klein (Rush Medical College, Chicago, USA) said that Henry V led the heavily outnumbered English army to victory at the Battle of Agincourt (1415) because he “figured out how to use an [...]

2019-10-15T12:11:36+00:00September 25th, 2019|Tags: , , |

TCT 2019: Companies reveal details of presentations

SS02 Several companies, including Boston Scientific and Corindus Vascular Robotics, have released details of their presentations at the upcoming 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA). Ancora Heart 25 September (Wednesday); 4.35pm; Room 203 Abstract: Hypertension and heart failure therapies (session II) heart failure therapies, TCT 88—six-month outcomes [...]

2019-09-20T15:44:12+00:00September 20th, 2019|Tags: , |